The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?

Expert Review of Neurotherapeutics
L CitromeKenji Maeda

Abstract

Brexpiprazole is a serotonin-dopamine activity modulator in clinical development for schizophrenia, adjunctive treatment of major depressive disorder, agitation in Alzheimer's disease and post-traumatic stress disorder. It is a partial agonist at 5-HT1A and D2 receptors with similar potency, and an antagonist at 5-HT2A and adrenergic α1B/2C receptors. Compared with aripiprazole, brexpiprazole is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors. This unique serotonin and dopamine modulatory activity has shown robust antipsychotic, antidepressant-like and anxiolytic activities, and limited extrapyramidal symptom liability with pro-cognitive efficacy in animal models. Phase III clinical trials have been successfully completed in schizophrenia and adjunctive use in major depressive disorder, with the US FDA approval obtained for these uses; Phase III studies in Alzheimer's disease and post-traumatic stress disorder are ongoing.

References

Jan 20, 2016·International Journal of Clinical Practice·L Citrome
Jan 13, 2016·Clinical Schizophrenia & Related Psychoses·Joseph McEvoy, L Citrome
May 28, 2016·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Feb 24, 2017·The Annals of Pharmacotherapy·Marija MarkovicMegan Maroney
Apr 20, 2017·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Jan 17, 2017·Expert Review of Neurotherapeutics·Ricardo P GarayPierre-Michel Llorca
Aug 31, 2019·Drugs·Jean-Michel Azorin, Nicolas Simon
Apr 8, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Hugo Geerts, Athan Spiros
Jul 19, 2017·Expert Opinion on Drug Discovery·Awais Aftab, Keming Gao
Aug 14, 2019·The International Journal of Neuropsychopharmacology·Jasmina MalletCaroline Dubertret
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura
Dec 20, 2018·Journal of Clinical Psychopharmacology·Jelena IvkovicMary Hobart
Aug 21, 2020·Molecular Psychiatry·Eva-Gunnel DucourneauPier-Vincenzo Piazza

Citations

Jan 1, 1991·Pharmacology, Biochemistry, and Behavior·K Njung'e, S L Handley
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Wolfarth, K Ossowska
Jan 1, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·N HaddjeriC de Montigny
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Apr 3, 2004·Nature Reviews. Drug Discovery·Bryan L RothWesley K Kroeze
Jan 5, 2005·The British Journal of Psychiatry : the Journal of Mental Science·A A Bolonna, R W Kerwin
May 10, 2005·Acta Psychiatrica Scandinavica. Supplementum·S R Marder
Oct 4, 2005·Expert Opinion on Pharmacotherapy·W Wolfgang Fleischhacker
Sep 22, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yuko FujitaKenji Hashimoto
Jul 24, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tamaki IshimaKenji Hashimoto
Oct 17, 2008·Pharmacological Reviews·Jeffrey A LiebermanJohn G Csernansky
Jun 23, 2009·Pharmacology & Therapeutics·Raffaella MolteniMarco Andrea Riva
Aug 25, 2009·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Lucy Y WangElaine R Peskind
Feb 16, 2010·Clinical Therapeutics·Emmanuel Stip, Valérie Tourjman
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Jan 31, 2012·Current Pharmaceutical Biotechnology·H Y MeltzerM Horiguchi
Nov 7, 2012·Handbook of Experimental Pharmacology·Nathalie Ginovart, Shitij Kapur
Feb 4, 2014·Psychopharmacology·Jan BrosdaHeinz H Pertz
Jun 21, 2014·The Journal of Pharmacology and Experimental Therapeutics·Kenji MaedaTetsuro Kikuchi
Jun 21, 2014·The Journal of Pharmacology and Experimental Therapeutics·Kenji MaedaTetsuro Kikuchi
Jul 6, 2014·BioMed Research International·Nevena DivacNatasa Cerovac
Jul 19, 2014·Journal of Psychiatric Practice·Ben Green

Related Concepts

United States Food and Drug Administration
Thiophenes
Phase 3 Clinical Trials
Schizophrenia
Serotonin Measurement
HTR2A wt Allele
Anti-Anxiety Effect
Serotonin
HTR1A
Antagonist Muscle Action

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.